Share

Initial Application of LTO

FDA Sponsor and CRO form initial application form

Your Browser Doesn't Support Canvas. Showing the Text Content of the PDF Instead: Republic of the Philippines
Department of Health
FOOD AND DRUG ADMINISTRATION

CENTER FOR DRUG REGULATION AND RESEARCH
SPONSOR (

) / CONTRACT RESEARCH ORGANIZATION (

)

SELF-ASSESSMENT TOOLKIT FORM
INITIAL APPLICATION OF LICENSE TO OPERATE

COMPANY NAME
:
COMPANY ADDRESS
:
Directions:
Fill out the form by ticking the applicable column. Provide remarks on the client’s column when necessary.
Accomplish in duplicate copies.

DOCUMENTARY REQUIREMENTS:

Yes

No

REMARKS
CLIENT

FDA

1. Application Form for LTO
Is the application properly filled out?
Is it duly notarized?
Are the signatories in the application form the approving
authority and qualified person as required under the
following circumstances?
(a) If single proprietorship – the owner as registered in DTI
(unless there is a different authorized person)
(b) If partnership/corporation – one of the incorporators or
authorized person as indicated in the board resolution or
Secretary’s Certificate
If the signatory is not the owner or one of the incorporators, as
the case may be:

Is the board resolution or Secretary’s Certificate notarized
and clearly identify the person authorized to sign for and in
behalf of the owner or corporation?













Is the person identified in the said document the same
person who signed the Application Form and/or Contract/
Agreement?
2. Proof of Business Name Registration
(a) For single proprietorship, Certificate of Business
Registration issued by the Department of Trade and
Industry (DTI)
Is the business name applied for LTO the same with that of
DTI registration certificate?
Is the DTI certificate still valid?
Is the owner appearing in the application form the same with
that of the DTI certificate?
Is the address of the establishment applying for LTO within
the territorial coverage? If the business address indicated in
DTI is different from the exact address as declared in the
application form, is there a clear copy of Business/Mayor’s
Permit or Barangay clearance indicating the complete
address of drug establishment?
(b) For corporation, partnership and other juridical person,
Certificate of Registration issued by the Securities and
Exchange Commission (SEC) and Articles of
Incorporation
Is the business name applied for LTO the same with that of
the SEC registration certificate? If the company uses another
business name style different from its corporate name, is an
amended SEC registration reflecting the same submitted?

1

 Is the address indicated in the SEC the same with the address
of the establishment applied for LTO?
o If the address in SEC is still occupied but the business
operation applied for LTO is located in a separate area,
is a clear scanned copy of Business /Mayor’s Permit or
Barangay clearance indicating the complete address of
drug establishment submitted?
o If the address in SEC is no longer occupied, is an
amended SEC registration reflecting the current
business address submitted?
 Is the type of activity and product applied for LTO indicated
in the Articles of Incorporation (Article II)?
(c) For government-owned or controlled corporation
 Is there a copy of the law creating the same? (if with original
charter)
3. Credentials of Qualified Person
 Is/are the name/s of qualified person/s identified in the list
submitted?
 Is the Certificate of Attendance to Basic and Advance Good
Clinical Practice (GCP) Training Courses of each qualified
person attached?
 Is the GCP Training attended within the last 3 years as
provided in the certificate?





4. Risk Management Plan
Are the risks for the establishment properly identified?
Are there plans of action for these identified risks?
Is there an established SOP for pharmacovigilance?
Is there an established SOP for handling regulatory mandates
from FDA, e.g. handling of GCP violations, etc?

5. Location Plan
 Does the sketch submitted indicate certain landmark?
 Is the GPS Coordinates included?
6. Proof of Payment
 Is the payment made according to the required fee?

ADDITIONAL REQUIREMENTS
(ON-SITE INSPECTION ONLY):
1.

Quality Management System

2. Quality Manual and Standard Operating Procedures
(a) Receipt and Dispatch
 Is there an orderly and secure system of accurately tracking the distribution and condition of investigational
products? Were vital IP information recorded such as but not limited to the lot/batch numbers, product description,
expiry date, quantities, temperature monitoring as applicable, etc.
(b) Handling of reports and other regulatory mandates
 Does the company maintain registry of reports (e.g., complaints, ADR, among others) with complete and accurate
action/s?
(c) Disposal of expired/deteriorated/ damaged and returned investigational products
(d) Cleaning of IP Storage Area (where applicable)
 Is there a regular conduct of pest control?
(e) Other relevant SOPs as required and applicable to the approved activities
3. Delegation of Authority and other Relevant Agreements
 Does activities in the Delegation of Authority in accordance with notified and authorized activities?
 Does the Delegation of Authority clearly define the roles and responsibilities of both Sponsor and CRO for specific
clinical research?
4.

Credentials of other qualified personnel

2

(a) Curriculum vitae
(b) Updated training records
(c) Other credentials, as required and applicable
5.

Proof of Ownership/Lease Agreement of the space/building

6.
(a)
(b)
(c)
(d)

Reference Materials (Hard copy or e-copy)
R.A. 3720, R.A 9711, R.A. 8203, R.A. 9502, existing FDA clinical-related issuances
International Conference on Harmonization (ICH) Safety and Efficacy Guidelines
Philippine National Health Research System (PNHRS) – National Ethical Guidelines for Health Research
WHO Annex 5 Guide to Good Distribution Practices (GDP) for Pharmaceutical Products and Annex 9 Guide to Good
Storage Practices for Pharmaceuticals, as applicable
(e) Other applicable reference materials
--- To be filled out by client: --Prepared by:
Signature:
Position (Qualified Person / Owner):
Date:
--- To be filled out by FDA Officer: --Remarks:
Decision:
Approval
Denial
Clarification
Inspection
Evaluated by:
Date:

--- To be filled out by CDRR: --Decision:
Approval
Clarification
Evaluated by:

Remarks:

Date:

3
 
Page of
Share